InvestorsHub Logo
Followers 26
Posts 2016
Boards Moderated 0
Alias Born 01/11/2012

Re: Protector post# 122494

Thursday, 05/16/2013 9:15:03 AM

Thursday, May 16, 2013 9:15:03 AM

Post# of 346164
<For the rest this abstract is, from where I stand, a disappointing one. It doesn't emphasize the big disadvantage of the Bavi arm vs the Control Arm when it comes to enrolled ECOG 2 patients. >

CP, I think you have to read this PR that just came out this morning

http://finance.yahoo.com/news/peregrine-pharmaceuticals-immunotherapy-bavituximab-highlighted-123000512.html

Notice this quote Abstract Conclusions: In this patient population with extensive disease burdens and limited treatment options

I think they are letting us know that there were significant burdens in the trial and will be highlighted in the actual poster.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News